Subscribe To
RETA / Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 14.5%: Will It Continue to Soar?
RETA News
By GuruFocus
August 1, 2023
CPMG Inc Acquires Significant Stake in Reata Pharmaceuticals Inc
CPMG Inc (Trades, Portfolio), a prominent investment firm, recently expanded its portfolio with the acquisition of a substantial number of shares in R more_horizontal
By Invezz
July 28, 2023
Reata Pharmaceuticals stock opened 50% up on Friday: what happened?
Shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) opened more than 50% up this morning after Biogen Inc (NASDAQ: BIIB) said it will buy the pharma co more_horizontal
By InvestorPlace
July 28, 2023
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
Reata Pharmaceuticals (NASDAQ: RETA ) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (NASDAQ: BIIB ). That de more_horizontal
By Zacks Investment Research
June 29, 2023
Reata Pharmaceuticals, Inc. (RETA) Moves 7.0% Higher: Will This Strength Last?
Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate more_horizontal
By Zacks Investment Research
June 19, 2023
Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS
Reata (RETA) gets FDA acceptance for the filing of new drug application supplement approval for Skyclarys' release. more_horizontal
By Zacks Investment Research
June 9, 2023
Why Is Reata Pharmaceuticals, Inc. (RETA) Up 6.9% Since Last Earnings Report?
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? more_horizontal
By Business Wire
June 6, 2023
Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global more_horizontal
By Zacks Investment Research
May 11, 2023
Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates
Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney more_horizontal